Parabilis Medicines Reports Q2 2026 Financial Results

What Happened

• On August 13, 2026, Parabilis Medicines, Inc. announced its financial results and business highlights for the quarter ended June 30, 2026. The company furnished a press release as Exhibit 99.1 to the Form 8-K and updated its corporate presentation for investor meetings, which was posted on the company’s investor relations website (https://parabilismed.com/) and furnished as Exhibit 99.2. The filing was signed by CFO Thomas Kotarakos.

Key Details

• Filing date: August 13, 2026; quarter covered: ended June 30, 2026.
• Press release with the quarterly results and business highlights is furnished as Exhibit 99.1.
• Updated corporate presentation (August 2026) is furnished as Exhibit 99.2 and is available on the company’s investor relations webpage.
• The Form 8-K includes the cover page interactive XBRL file (Exhibit 104).

Why It Matters

• This 8-K is the company’s public release of its most recent quarterly results and business update — essential source documents for investors to review actual earnings, revenue, cash position, and program progress.
• The updated investor presentation may contain refreshed financial metrics, operational highlights, or program status that investors use to assess near-term prospects and capital needs.
• Retail investors should read the furnished press release and presentation on Parabilis’ website to see the detailed figures and narratives behind the company’s reported quarter.